Meta Platforms is the IBD Stock of the Day for Monday. Shares of the Facebook parent company have formed a flat base pattern after bouncing back last week from a slight earnings letdown. Please watch ...

Hims stock rose early Tuesday after compounded weight-loss drugs helped build on a "robust" trajectory for Hims & Hers Health ...

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...

Direct costs associated with IBD include ambulatory visits to gastroenterologists, emergency department visits, admissions ...

A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.

The firm said they posted better-than-expected initial data from SPY001 and thinks the data incrementally de-risks its lead asset and broad pipeline, which could offer best-in-class dosing and ...

Aeglea Biotherapeutics Inc. ( (SYRE) ) has released its Q3 earnings. Here is a breakdown of the information Aeglea Biotherapeutics Inc.

Nanoparticles that turn inflammation into propulsion power deliver targeted IBD treatment, enhancing precision and efficacy.

Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...

Bhubaneswar: Smruti Swarup Patra, known by his stage name ‘Nextion’, has emerged as the first runner-up in the ‘Ultimate ...

Anticipation builds for Indias Best Dancer Season 4 finale with Arjun Kapoor and Tiger Shroff. Expect thrilling performances ...

P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis," published in the November 2024 issue of Gastroenterology by Hu et al. Since 2015, CT-P13, a ...